SNTA stock gained after the company said that ganetespib, administered as monotherapy to combat metastatic breast cancer, had demonstrated “highly encouraging single-agent activity in both HER2+ and triple-negative disease” in the ENCHANT-1 trial. The study is a single-arm multi-center Phase 2 proof-of-concept study that aims to assess the drug’s performance. The interim results were presented at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland.
In a statement, SNTA noted that the early results “warrant expanded study of ganetespib in this metastatic disease setting.”
On Wednesday, SNTA stock closed at $4.75 a share. SNTA stock has declined more than 30% over the past year.
More Drug Stock News: